MK-2870 with ChemotherapyA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06428409

Conditions

Colorectal Cancer

Pancreatic Ductal Adenocarcinoma

Biliary Tract Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab tirumotecan

Fluorouracil (5-FU)

Leucovorin (LV) or levoleucovorin

Rescue medication

Supportive care measures

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-07-01.